Rising Diabetic Population Fuels Onychomycosis Market Growth: A Significant Driver Propelling The Onychomycosis Market In 2025

The Onychomycosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Onychomycosis Market Size and Projected Growth Rate?
The market for onychomycosis has seen substantial growth in recent times. The market size is predicted to rise from $3.63 billion in 2024 to $3.83 billion in 2025, with a compound annual growth rate (CAGR) of 5.4%. Factors contributing to the growth during the historical period include limited treatment choices, an aging populace, a higher prevalence of diabetes, the growth of the pharmaceutical sector, and a heightened awareness of fungal infections.

Expectations are high for the onychomycosis market, as it is predicted to experience notable growth in the coming years. A robust compound annual growth rate (CAGR) of 5.9% is expected to propel the market to $4.81 billion by 2029. Several factors are likely to contribute to this growth, including the adoption of combined drug treatments, increased healthcare spending, escalating awareness efforts about onychomycosis, the enlargement of telemedicine services, and the progression in the field of topical drug formulations. Within the forecast period, significant trends are likely to emerge, including the incorporation of digital technology in onychomycosis diagnosis and treatment, a surge in the availability of over-the-counter antifungal products, the advent of more patient-friendly treatment schemes, a focus on personalized onychomycosis treatments, and a rise in collaborative efforts among pharmaceutical companies for research and development.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12197

What Are the Major Segments in the Onychomycosis Market?
The onychomycosis market covered in this report is segmented -

1) By Type: Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis, Other Types
2) By Treatment: Drug Treatment, Topical Therapy, Other Treatments
3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:
1) By Distal Subungual Onychomycosis (DSO): Dermatophyte Infections, Mixed Infections
2) By White Superficial Onychomycosis (WSO): Trichophyton Mentagrophytes Infections, Other Non-Dermatophyte Infections
3) By Proximal Subungual Onychomycosis (PSO): Associated with Nail Psoriasis, Fungal Infections In Immunocompromised Patients
4) By Candida Onychomycosis: Candidal Nail Infections, Mixed Fungal-Candida Infections
5) By Other Types: Total Nail Dystrophy, Secondary Onychomycosis

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12197&type=smp

What Are The Driving Onychomycosis Market Evolution?
The increasing number of people suffering from diabetes is predicted to drive the expansion of the onychomycosis market. Diabetes, a persistent illness, occurs due to either inadequate insulin production by the pancreas or poor insulin utilization by the body. Onychomycosis is a prevalent foot issue among diabetic persons, which can be maintained by controlling and managing related complications. Consequently, the escalating diabetes occurrence amplifies the demand for the onychomycosis market. As an example, the National Health Service, a UK government department, reported in June 2024 that they had identified around half a million (549,000) new individuals at risk of type 2 diabetes in England in 2023. This raised the total count of people suffering from non-diabetic hyperglycemia or pre-diabetes, and registered with a GP to 3,615,330. This marked a considerable increase of nearly 20% compared to 3,065,825 in 2022. As a result, the growing prevalence of diabetes is stimulating the development of the onychomycosis market.

Which Firms Dominate The Onychomycosis Market Segments?
Major companies operating in the onychomycosis market include Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Galderma Laboratories LP, Aurobindo Pharma Limited, Cipla Inc., Dr.Reddy's Laboratories Ltd., Apotex Inc, Lupin Limited, Amneal Pharmaceuticals Inc., Alembic Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Mayne Pharma Group Limited, Wockhardt Ltd., Jubilant Cadista Pharmaceuticals Inc., Moberg Pharma AB, Medimetriks Pharmaceuticals Inc., Blueberry Therapeutics Ltd., Hallux Inc., NovaBiotics Ltd., Zydus Cadila Healthcare Limited.

What Trends Are Expected to Dominate the Onychomycosis Market in the Next 5 Years?
In the onychomycosis market, a major trend being observed is product innovation. The leading businesses are innovating new products in an attempt to reinforce their market position. For example, Vanda Pharmaceuticals Inc., a biopharmaceutical company based in the US declared in January 2024 that the FDA had approved their VTR-297 for the treatment of onychomycosis. VTR-297 is a small molecule histone deacetylase (HDAC) inhibitor with a unique ability to show antifungal activity specifically against dermatophytes and various fungi. This action mechanism is essential for efficiently attacking the pathogens causing onychomycosis. The drug is intended for topical application, enabling direct application to the affected nails. This method of localized delivery reduces systemic exposure and avoids possible side effects that can be related to oral antifungal treatments.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report

Which Is The Largest Region In The Onychomycosis Market?
North America was the largest region in the onychomycosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Onychomycosis Market?
2. What is the CAGR expected in the Onychomycosis Market?
3. What Are the Key Innovations Transforming the Onychomycosis Industry?
4. Which Region Is Leading the Onychomycosis Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.